Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo. Median nebulization times were less than four minutes for both doses in the study. Initial review of the data has not identified any serious adverse events attributed to study drug. Patients continue to be treated in a 52-week safety study to collect long-term safety data on the two doses under investigation.

"Based on our initial review of these data, both the placebo and study groups experienced improvements in asthma symptoms, but the differences were not statistically significant. We observed a higher than expected response in the placebo group, starting as early as one week after randomization and continuing throughout the 12 week treatment period," said Timothy S. Nelson, Chief Executive Officer of MAP Pharmaceuticals. "We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program. The Company remains dedicated to developing therapies for children suffering from asthma."

About the AstraZeneca Collaboration

MAP Pharmaceuticals and AstraZeneca have a collaboration agreement to develop and commercialize UDB in the United States, and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

About the Study

In this randomized, double-blind, placebo-controlled study, 360
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...
(Date:5/17/2013)...  Atossa Genetics, Inc. (NASDAQ: ATOS ), The ... , Chief Financial Officer & General Counsel, will present ... May 30, 2013, in New York City ... Company,s presentation is scheduled to begin at 3:30 p.m. EDT ... the webcast, go to www.atossagenetics.com . For ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... systems, announced today that the United States Food and ... Drug application(IND) for ORMD-0801, its oral insulin capsule. ... clearance to proceed," stated Nadav Kidron ... major milestone for Oramed and we look forward to ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... 2011 Reportlinker.com announces that a new ... catalogue: Global Radiation Therapy ... This report analyzes the ... US$ Million by the following product segments: ...
... 2011 Reportlinker.com announces that a new market ... Top 1000 Pharmaceutical Wholesalers ... The Global Pharmaceuticals Wholesalers Industry ... This report is an in-depth financial ...
Cached Medicine Technology:Global Radiation Therapy Equipment Industry 2Global Radiation Therapy Equipment Industry 3Global Radiation Therapy Equipment Industry 4Global Radiation Therapy Equipment Industry 5Global Radiation Therapy Equipment Industry 6Global Radiation Therapy Equipment Industry 7Global Radiation Therapy Equipment Industry 8Global Radiation Therapy Equipment Industry 9Global Radiation Therapy Equipment Industry 10Global Radiation Therapy Equipment Industry 11Global Radiation Therapy Equipment Industry 12Global Radiation Therapy Equipment Industry 13Global Radiation Therapy Equipment Industry 14Global Radiation Therapy Equipment Industry 15Global Radiation Therapy Equipment Industry 16Global Radiation Therapy Equipment Industry 17Global Radiation Therapy Equipment Industry 18Global Radiation Therapy Equipment Industry 19Global Radiation Therapy Equipment Industry 20Global Radiation Therapy Equipment Industry 21Global Radiation Therapy Equipment Industry 22Global Radiation Therapy Equipment Industry 23Global Radiation Therapy Equipment Industry 24Top 1000 Pharmaceutical Wholesalers (Global) 2Top 1000 Pharmaceutical Wholesalers (Global) 3Top 1000 Pharmaceutical Wholesalers (Global) 4
(Date:5/18/2013)... 19, 2013) Each year, the American Gastroenterological ... contributions and achievements in gastroenterology through its esteemed ... distinguished and talented individuals who work tirelessly to ... we are pleased to announce the 2013 recognition ... colleagues for their tremendous contributions to our field," ...
(Date:5/18/2013)... May 19, 2013 Illuminations is proud to ... Caetano. Seminars will take place over the course of ... June 7, and Saturday, June 8, 2013. , Inner Child ... but focuses on the attitudes, patterns and coping mechanisms that ... Participants will learn to live a more integrated and balanced ...
(Date:5/18/2013)... MOOSGO.COM published an original art book for ... a group of artists who share their creations based on ... paintings. Exclusively for iPad . , This work ... videos that reflect the signature idiosyncrasy and passion of tango. ... iBook Store and it includes a free trailer of ...
(Date:5/18/2013)... 18, 2013 In a May 14, ... Double Mastectomy After Discovering Cancer Gene,” Fox News reported ... upon learning that she carried a gene that doctors ... cancer and a 50 percent risk of ovarian cancer ... on May 16, 2013 with a blog post entitled ...
(Date:5/18/2013)... 2013 Transvaginal mesh lawsuits ... move forward in a consolidated litigation underway in New ... According to a notice on the Court’s website, the ... litigation will be held on Wednesday, May 22nd. ... in the proceeding on behalf of women who suffered ...
Breaking Medicine News(10 mins):Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:New Art Book for iPad: Tango Art 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3
... been able to use testosterone gel to effectively slow down ... 10 men took part in the research, all had milder ... doctors determine whether the treatment really works. Still, the researchers ... shrinking of their brains returned to the normal levels expected ...
... Towns in the country namely Kottayam, Puri, Tirupati, Ujjain, ... phase of the Eco-City Programme . The projects undertaken ... respective towns are under various stages of implementation. The ... Plan is being continued during the first year of ...
... officials across U.S are worried about falling rates in mammography ... Centers for Disease Control (CDC), the percentage of women ... risk, have fallen from 70 percent in 2000 to 66 ... Some say they correspond with a fall in the use ...
... of migraine and other headaches are more likely to have ... lead to severe vision problems or blindness, than those ... in the May 15, 2007, issue of Neurology, the scientific ... the study, researchers reviewed the headache history and eye health ...
... treadmill, could help obese employees shed up to 30 kg in ... desk allows people to work at a computer while simultaneously walking ... ,Designed by the authors, the steel frame of the device ... by four locking rubber wheels, so that it can be moved ...
... The 60-year-old macho Sylvester Stallone admitted to possessing the growth hormone ... last. ,Stallone was then in Australia to promote his ... when the confession came to light a couple of days ago. ... a maximum fine of A$22,000 ($18,330, 9,200) in court, much lower ...
Cached Medicine News:Health News:Multiple Sclerosis Could Be Checked Through Testosterone Gel 2Health News:Multiple Sclerosis Could Be Checked Through Testosterone Gel 3Health News:Mammogram Rates On The Decline In America 2Health News:Mid-Life Headaches May Increase Risk of Vision Problems 2Health News:walk and Work Desk Could Help Obese Workers to Shed Weight 2Health News:Sylvester Stallone Admits He Tried to Smuggle Banned Growth Hormone to Australia 2
... Practice Management software- ... system of Software, Support, ... offices of Optometry, Ophthalmology, ... streamlines office operations, allowing ...
... hematology system delivers a full ... for speed and accuracy, this ... with impressive productivity. The Advia ... its own or twinned with ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
Medicine Products: